CASI Pharmaceuticals gets OK for clinical trial of leukemia drug

Rockville-based pharmaceutical company CASI Pharmaceuticals Inc. received approval Thursday from the National Medical Products Administration (NMPA) for a registration clinical trial in China of a drug for the treatment of a type of leukemia. The drug, a of vincristine sulfate lipsome injection named Marqibo, is geared for the treatment of adult patients with Philadelphia chromosome–negative (Ph‒) acute lymphoblastic ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *